作　　者： (李欣颖）; (张大庆）;

机构地区： 中国医科大学附属盛京医院心内科,沈阳110004

出　　处： 《实用药物与临床》 2017年第8期956-962,共7页

摘　　要： 心力衰竭是各种心血管疾病的最终归宿,有较高的发病率和死亡率。目前指南对于射血分数降低的心衰患者的常规药物治疗可以显著降低其发病率和死亡率。近年研究显示,新药依伐布雷定和缬沙坦/沙库比曲可显著改善射血分数降低的心衰患者的预后,已被批准应用于临床。一些新的治疗手段如机械性辅助装置、干细胞治疗也为心衰患者带来新的曙光。本文对心衰的诊断、治疗,以及慢性心衰的规范化管理进行综述。 Heart failure is the ultimate outcome of various cardiovascular diseases,with high morbidity and mortality.Current guidelines for conventional drug therapy in patients with reduced ejection fraction heart failure（HFrEF） can significantly decrease their morbidity and mortality.In recent years,clinical trials have shown that ivabradine and entresto can obviously improve the ejection fraction and prognosis of patients with HFrEF,which have been approved by FDA for clinical use.Some emerging approaches such as mechanical aids devices and stem cell therapy for patients with heart failure progressively bring a new dawn.This paper reviews the diagnosis,treatment and the standardized management of patients with heart failure.

关 键 词： 心力衰竭 药物治疗 沙库比曲 缬沙坦 依伐布雷定 托伐普坦